Finding. CHO cells in fed-batch do not randomly fade. They take a conserved walk from proliferation through a metabolic transition into a terminal state that burns fatty acids in mitochondria and peroxisomes, remakes lipids, carries an oxidative load, and lights ferroptosis pathways. Fancy feeds postpone that walk with glutathione-style defense. They do not buy a matching increment of antibody. The cell spends the carbon on staying alive.
Why this paper matters
Fed-batch optimization is still folklore. A longitudinal proteome/metabolome that names FAO and ferroptosis as the late constraint is a parts list for host engineering. The mitochondrial half is β-oxidation as the unproductive endgame, not a desirable OXPHOS boost.
The trade-off sentence is the industrial one: survival and titer are not the same objective.
What they actually measured
Time-series proteomics and intracellular metabolomics across feeds and an intensified seed; conserved trajectory; FAO/ferroptosis signature; feed delay versus titre.
How to read the score
High sixties. Real mitochondrial FAO, bioprocess not biomedicine. Score 68.
What to do with it
If you engineer CHO or design feeds, target late FAO and ferroptosis and measure titer, not only viability. The directional implication is that late-stage CHO survival is a mitochondrial/peroxisomal fat-burning, ferroptosis-adjacent program that steals productivity.